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prescribed drugs for arthritis, inflammation, and cardiovascular
protection. However, they cause gastrointestinal complications.
The pathophysiology of these complications has mostly been
ascribed to non steroidal anti inflammatory drugs’ action on the
cyclooxygenase inhibition and the subsequent prostaglandin defi 
ciency. However, recent clinical demonstrated the prevalence of
non steroidal anti inflammatory drugs induced small intestinal
mucosal injury is more often than previously expected. In this
review, we discuss the defense mechanisms of stomach, and the
pathophysiology of non steroidal anti inflammatory drugs induced
injury of stomach and small intestine, especially focused on non 
steroidal anti inflammatory drugs’ action on mitochondria.
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Introduction Non-steroidal anti-inflammatory drugs (NSAIDs) such as
aspirin and indomethacin are the most commonly prescribed
drugs for arthritis, inflammation, and cardiovascular protection.
However, they cause gastrointestinal complications such as ulcers
and erosions. The pathophysiology of these complications has
mostly been ascribed to NSAID’s action on the cyclooxygenase
(COX) inhibition and the subsequent prostaglandin (PG) defi-
ciency.(1) In 1970s and 1980s, under the concept of cytoprotection,
extensive researches have revealed the role of PG in gastric
mucosal defense system.(1)
Recent clinical researches shed a light on the NSAID-induced
small intestinal mucosal injury. Capsule endoscopic examinations
revealed that NSAID induced mucosal damages including erosions
and ulcerations in small intestines more often than previously
expected.(2) Although gastric mucosal injuries are considered to
be associated with the gastric acid, these results suggested that
NSAIDs induced mucosal injuries independently with the acid,
since there is no acid-secreting cell in small intestines. Therefore,
the treatment for NSAID-induced small intestinal mucosal injuries
should include medications other than conventional acid-reducing
agents such as histamine 2 receptor antagonists (H2RAs) and
proton pump inhibitors (PPIs).(3–6) The pathophysiological concept
that will explain the NSAID-induced injuries of both stomach and
small intestines is needed.
In this review, we discuss the defense mechanisms of stomach,
and the pathophysiology of NSAID-induced injury of stomach and
small intestine.
Gastric Mucosal Defense Mechanisms
Gastric mucosal injury occurs when the causative agents such
as gastric acid and NSAIDs overwhelm the mucosal defense. The
gastric defense mechanisms can be divided into three major
components: pre-epithelial, epithelial, and post-epithelial defense
mechanism (Table 1).(7,8)
The pre-epithelial defense mechanism consists mainly of a
mucous layer that contains mucous, bicarbonate and surface active
phospholipids, and prevents epithelial cells from the contact
with luminal noxious agents such as gastric acid. Mucous and
bicarbonate are secreted by gastric epithelial cells. As a result, the
pH at the surface of gastric mucosal epithelial cells normally is
maintained in the neutral range when the pH at the gastric luminal
surface reaches 1 to 2.
The surface epithelial cells are served as the second line of
defense. Not only their tight junction complexes to limit the
diffusion of hydrogen ions and their secretion of mucous and
bicarbonate, but they migrate into a site of injuries to restore a
damaged region (restitution).
Mucosal blood flow within the gastric submucosal layer com-
prises the post-epithelial defense mechanism. Blood flow provides
an adequate supply of micronutrients and oxygen in order for
epithelial cells to secrete mucous and bicarbonate. It also removes
acid and other toxic metabolic by-products.
PGs play a key role in gastric epithelial defense by enhancing
the pre-epithelial, epithelial, post-epithelial defense mechanisms:
PGs regulate the secretion of bicarbonate and mucous, inhibit
gastric acid secretion, and are important in maintaining epithelial
cell restitution and mucosal blood flow.
N
Table 1. Gastric mucosal defense mechanisms
1. Pre epithelial mechanisms
• Mucous
• Bicarbonates
• Surface active phospholipids
2. Epithelial mechanisms
• Tight junction complex
• Restitution
• Growth factors
• Cell proliferation
3. Sub epithelial mechanisms
• Microcirculation of blood
• Leukocytesdoi: 10.3164/jcbn.10 79
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Proposed Mechanisms of NSAID Induced Stomach Injury
The defense mechanisms of stomach against NSAID can be
divided into 2 categories: PG-dependent mechanism and non-PG-
dependent mechanism.
The pathophysiology of PG dependent NSAID induced
stomach injury. Since PGs play a critical role in maintaining
gastric mucosal defense system, the inhibition of COX leading to
decreased mucosal PGs is considered as the most important in the
pathogenesis of NSAID-induced gastric damage. Aspirin inhibits
COX irreversibly, while other NSAIDs inhibit COX in a reversible,
concentration-dependent manner.(8) Two COX isoforms were
identified in early 1990s in mammalian cells, COX-1 and COX-2.
COX-1 is constitutively expressed in most of tissues including
stomach and responsible for maintaining gastric mucosal integrity
at base line, whereas COX-2 participates in inflammation. Gastric
injury was thus considered to be ascribed to gastric mucosal PG
deficiency by COX-1 inhibition. In human stomach, little or no
COX-2 protein and activity was demonstrated, while abundant
COX-1 protein and activity was demonstrated.(9) Therefore,
NSAIDs that selectively inhibit COX-2 were developed and
applied in a clinical setting.
More recently, experimental data in animal demonstrated that
for gastric ulceration to occur, both COX-1 and COX-2 must be
inhibited.(10) The result challenges the concept that only COX-1
plays a housekeeping role in the stomach. Recent researches
suggested that both COX-1 and COX-2 may play a role in PG
synthesis and maintenance of gastric mucosal integrity, and that
COX-2 plays a “back-up” role by alleviating PG deficiency which
is induced by COX-1 inhibition.(1)
The pathophysiology of PG independent NSAID induced
stomach injury
The ‘trapping’ theory. The mechanism of NSAID-induced muco-
sal injury that is not dependent with systemic PG deficiency
includes local injuries of these agents. Most NSAIDs are weak
organic acids. In gastric juice, they are non-ionized and lipid
soluble. These NSAIDs diffuse across gastric mucosal epithelial
cell membranes into the cytoplasm, where pH is neutral. In neutral
pH, NSAIDs are converted into the re-ionized and relatively
lipophobic form. Therefore NSAIDs are trapped and accumulate
within cells, leading to the cellular injury.(11) The mechanisms
that NSAID induced local injury to the mucosal cell remain to be
elucidated, but in vitro studies including ours proposed mito-
chondria are the primary target of NSAIDs, which is discussed in
later sections.
This ‘trapping’ theory, however, may not be applied to small
intestinal mucosa, where luminal pH is almost neutral. Consid-
ering the in vitro experimental results that NSAIDs are indeed
absorbed into small intestinal cells in neural pH, we think the
“trapping” may not be essential for inducing small intestinal
injuries, but may accelerate the extent of injury by increasing the
absorption of NSAIDs.
Mitochondria, lipid peroxidation, and apoptosis. A mitochon-
drion is a membrane-enclosed organelle with 0.5 to 10 micro-
meters range. In eukaryotic cells, mitochondria generate most of
the cell’s chemical energy supply of adenosine triphosphate
(ATP). In addition to energy metabolism, the regulation of cell
death has recently considered as a second major function of
mitochondria.(12) Mitochondrial respiratory chain is the major
source of reactive oxygen species (ROS), which are mainly
generated at Complex I and III of the respiratory chain. More
importantly, the mitochondrial respiratory chain is, at the same
time, an important target for the damaging effects of ROS. ROS
from mitochondria play an important role in the release of
cytochrome c and other pro-apoptotic proteins, which can trigger
caspase activation and apoptosis.(12)
Mitochondria are considered as the target intracellular organelle
of absorbed NSAIDs. NSAIDs inhibit, or uncouple, oxidative
phosphorylation to dissipate the mitochondrial transmembrane
potential (MTP), leading to the liberation of cytochrome c from
mitochondrial intermembranous space into cytosol and to the
release of ROS such as superoxide (O2￿−) and hydrogen peroxide
(H2O2), thereby causing caspase 9 and caspase 3 activation and
cellular lipid peroxidation, all resulting in cellular apoptosis.(13–16)
The uncoupling of mitochondria also decreased the intracellular
ATP concentration, leakage of Ca2+ out of mitochondria, cellular
osmotic imbalance and a loss of control over intracellular junc-
tions, resulting in increased permeability and subsequent mucosal
damages.(17)
The Pathophysiology of NSAID Induced Small Intestinal
Injuries
The pathophysiology of NSAID-induced small intestinal injuries
was less well understood than that of gastric injuries. For the
pathophysiology of NSAID-induced small intestinal injuries, a
three step hypothesis was proposed (Fig. 1).(18) Firstly, NSAIDs
that were absorbed into the enterocytes inhibit the mitochondrial
oxidative phosphorylation. Secondly, the inhibition of oxidative
phosphorylation causes dysfunction of the tight intracellular
junctions and increases the intestinal permeability.(2) Thirdly,
through the mucosal barrier whose permeability was increased,
the enterocytes are exposed to luminal contents, such as bile
acids, hydroeolytic/proteolytic enzymes, pancreatic secretions,
and finally intestinal bacteria, resulting in neutrophil chemotaxis
with activation of neutrophils causing nonspecific inflammation
and ulceration.(19)
The uncoupling of mitochondrial oxidative phosphoryal 
tion. In these pathophysiological processes, the NSAID-induced
inhibition of oxidative phosphorylation in mitochondria is
considered as the main underlying mechanism.(2) The electron
microscopic study of small intestine of rats treated with indo-
methacin revealed, within 1 h of treatment, swelling, vacuolation,
ballooning and disruption of enterocyte mitochondria, which is
consisted with the presence of the uncoupling of mitochondrial
oxidative phosphorylation.(20)
The exact biochemical mechanism how NSAIDs inhibit, or
Fig. 1. The proposed pathophysiology of NSAID induced small intesi 
tinal mucosal injury. NSAIDs were absorbed into the enterocytes, and
uncouples the mitochondrial oxidative phosphorylation. This un 
coulping causes dysfunction of the tight intracellular junctions and
increases the intestinal permeability. Through the mucosal barrier
whose permeability was increased, the enterocytes is exposed to
luminal aggressive contents such as bile acids, hydroeolytic/proteolytic
enzymes, pancreatic secretions, and finally intestinal bacteria, resulting
in neutrophil chemotaxis with activation of neutrophils causing non 
specific inflammation and ulcerations. J. Clin. Biochem. Nutr. | March 2011 | vol. 48 | no. 2 | 109
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“uncouple”, the mitochondrial oxidative phosphorylation is
unclear. In vitro studies demonstrated that the uncoupling effect
of NSAIDs is at least partly due to up-regulation of proapoptotic
proteins and/or down regulation of antiapoptotic proteins of the
Bcl-2 family,(21) followed by the induction of the mitochondrial
permeability transition pore (MPTP).(22,23) The MPTP is a protein
pore that is induced in the membranes of mitochondria under
certain pathological conditions or pharmacological agents (Fig. 2).
Some in vitro studies demonstrated that NSAIDs induce, through
up-regulation of proapoptotic proteins and/or down regulation of
antiapoptotic proteins of the Bcl-2 family, the translocation of
proapoptotic Bax protein toward mitochondria, which further
induces and opens MPTP.(21) MPTP opening leads to a decrease of
mitochondrial transmembrane potential, resulting in the inhibition
of mitochondrial oxidative phosphorylation. Opening of MPTP
also leads to cytochrome c realase into the cytosol, resulting in
cellular apoptosis.(21)
This process was also applied to gastric epithelial cells. Our
study  in vitro using gastric RGM1 cells also confirmed that
indomethacin treatment induced a decrease of mitochondrial
transmembrane potential and induced apoptotic protein activa-
tions (cleaved caspase 3 and 9), which was inhibited by an
antiulcer drug rebamipide (Fig. 3).(16)
The immediate consequence of uncoupling of oxidative phos-
phorylation is a reduction of ATP production and subsequent
leakage of Ca2+ out of mitochondria into cytosol.(24,25) The ATP
deficiency and the accumulation of adenosine diphosphate (ADP)
and adenosine monophosphate (AMP) stimulate glycolysis in
enterocytes.(26) The maximally stimulated glycolysis induced the
production of lactate rather than acelyl CoA, because pyruvate
dehydrogenase activities are low in enterocytes.(17) The increased
cytosolic Ca2+ activates Ca2+-sentitive enzymes, proteases, endo-
nucleases, and phospholipases, and reportedly potentiates cellular
lipid peroxidation.(27)
The increased intestinal permeability. The mechanisms
that the inhibition of oxidative phophorylation increases intestinal
permeability are not well understood, but are explained as follows:
the inhibition of oxidative phophorylation leads to intracellular
ATP deficiency and leakage of calcium (Ca2+) from mitochondria,
both of which in turn causes increased cytosolic Ca2+, increased
production of ROS, disturbed sodium/potassium (Na+/K+) ratios
with cellular osmotic imbalance, resulting in the dysfunction of
the tight intracellular junctions and increased permeability.(2,17,19,28)
In addition, NSAIDs-induced cellular apoptosis may involve in
the increased permeability.(29)
The role of intestinal permeability in NSAID-induced small
intestinal injury is extensively examined by Bjarnason and
colleagues.(18,28) The increased intestinal permeability, which is
assessed by measuring of urinary recovery of a variety of orally
administered test probes such as 51Cr-labeled ethylenediamine-
tetraacetate (51Cr-EDTA), is induced within 12 h of NSAID
administration in human, and it relates quantitatively to NSAID
potency to inhibit COX, and is partly reversed by concomitant
PG administration.(30) Interestingly, NSAIDs induced little or no
increased permeability in stomach of human volunteers.(31,32)
These results suggest the difference between the underlining
mechanisms of NSAID-induced gastropathy and those of entero-
pathy.
The inflammation. Once the intestinal barrier has been
broken, the sequence of events leading to inflammation is
determined by the luminal aggressive factors. It is notable that
the difference of aggravating factors between small intestine and
stomach may explain the different biological responses and
therefore the macroscopic lesions.(17) The aggravating factors of
stomach are gastric acid and pepsin, whereas those of small
intestine are bile acid, hydroeolytic/proteolytic enzymes, pancreatic
secretions, and intestinal bacteria.
The important role of bile acid an aggravating factor of NSAID-
induced small intestinal injury was suggested by the result of an in
vivo study that bile duct ligation reduced the prevalence of the
Fig. 2. Gastric epithelial RGM 1 cells were cultured with control
medium, 1 mM indomethacin containing medium, and 1 mM indo 
methacin containing medium with 1 h 1 mM rebamipide pretreatment.
Cells were immunohistochemically stained with monoclonal antibodies
for caspase 3 and caspase 9. The fluorescence intensities of both caspase
3 and 9 were significantly increased in indomethacin treated cells
(*:  p<0.05 vs control). However, the fluorescence intensities of cells
pretreated with rebamipide were significantly reduced than those in
cells treated with indomethacin alone (#: p<0.05 vs indomethacin alone).
Fig. 3. The mitochondrial permeability transition pore. The MPTP is a
protein pore that is induced in the membranes of mitochondria under
certain pathological conditions or pharmacological agents. NSAIDs
induce, probably through up regulation of proapoptotic proteins and/or
down regulation of antiapoptotic proteins of the Bcl 2 family, the trans 
location of proapoptotic Bax protein toward mitochondria, which
further induces and opens MPTP. MPTP opening leads to a decrease of
mitochondrial transmembrane potential, resulting in the inhibition of
mitochondrial oxidative phosphorylation. Opening of MPTP also leads
to cytochrome c realase into the cytosol, resulting in cellular apoptosis.doi: 10.3164/jcbn.10 79
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lesions significantly.(33) Although the exact biological mechanisms
were unclear, it is supposed that bile acid may further damage
cellular membranes to increase intestinal permeability, or NSAIDs
conjugated in bile may be converted into free, active form through
the bacterial deconjugation in small intestine.
The role of bacteria as an aggravating factor of NSAID-induced
small intestinal injury is suggested by the experimental results that
NSAIDs induced very few intestinal lesions in germ-free animals
and that pretreatment with antimicrobials reduced NSAID-
induced small intestinal damages.(34–36)
The neutrophil infiltration is essential in the development of
macroscopic lesion. The microbial invasion and the damaged
mucosa are considered as the main neutrophil chemoattractant.
Generated ROS from activated neutrophils results in the mucosal
damage, the finding experimentally confirmed that the prevention
of neutrophil infiltration by induction of neutropenia inhibited
NSAID-induced macroscopic mucosal damage.(37)
The role of PG deficiency in NSAID induced small intestinal
injury. The role of PG deficiency in NSAID-induced small
intestinal injury is poorly understood, and there is controversy
regarding whether PG deficiency is considered as the main causes
of NSAID-induced small intestinal injury. Some studies demon-
strated the protective effects of PG on NSAID-induced small
intestinal injuries in animal models(38–40) and the PG deficiency in
small intestine is proposed as the main cause.(11,41)
However, recent experimental studies demonstrated that the
PG deficient does not have a major role in the small intestine
injuries.(42,43) Somasundram et al. studied in a rat model that was
designed to allow dissociation of the effects and pathophysio-
logical consequences of the ‘topical’ mitochondrial inhibition and
the ‘systemically’ mediated COX inhibition.(44) They demonstrated
that the treatment of parenteral aspirin decreased mucosal PGs
without affecting mitochondria, cellular permeability and caused
no inflammation, and that the treatment of dinitrophenol, an
uncoupling agent, increased intestinal permeability and caused
inflammation without affecting intestinal PG levels. They con-
cluded that the deficient endogenous PG production is not
sufficient to alter intestinal permeability in short term.(44)
Conclusion
This review is focused on the pathophysiology of NSAID-
induced gastroenteropathy, especially on PG-independent, mito-
chondria-dependent small intestinal injury.
It seems that the framework of pathophysiology of NSAID-
induced mucosal injury may differ in stomach and in small
intestine. The relative physiological importance of PGs in main-
taining mucosal defense system between stomach and small
intestine may contribute to the experimental and clinical results
of NSAID-induced mucosal injuries. In stomach, because of the
essential role of PG, NSAID-induced mucosal injury can be
explained by the PG deficiency, and the exogenous PG treatment
had protective effects in vitro and in vivo. On the other hand, in
small intestine, NSAID-induced mucosal injury cannot be
explained, although controversy exists, by the PG deficiency
alone. The difference in aggressive factors of mucosal epithelium
may affect the pathophysiology of NSAID-induced mucosal
injury: gastric acid in stomach and luminal bacteria in small
intestine. The reduction of gastric acid secretion in stomach and
the sterilization of bacteria in small intestine had a protective
effect on NSAID-induced mucosal injuries, and not vice versa.
However, we emphasize the importance of the uncoupling of
mitochondrial oxidative phosphorylation as a common first step
in NSAID-induced mucosal injury both in stomach and in small
intestine. We think a novel therapeutic approach against NSAID-
induced gatrointestinal mucosal injuries should include agents that
prevent the uncoupling oxidative phosphorylation of mitochondria
in epithelial cells.
Abbreviations
NSAIDs non-steroidal anti-inflammatory drugs
COX-1 cyclooxygenase-1
COX-2 cyclooxygenase-2
PG Prostaglandin
H2RAs histamine 2 receptor antagonists
PPIs proton pump inhibitors
ATP adenosine triphosphate
ROS reactive oxygen species
MTP mitochondrial transmembrane potential
O2￿− superoxide
H2O2 hydrogen peroxide
MPTP mitochondrial permeability transition pore
AMP adenosine monophosphate
ADP adenosine diphosphate
EDTA ethylenediaminetetraacetate
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